Briefing
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer; trastuzumab deruxtecan versus standard-of-care treatment in ctDNA-positive HER2-positive/HER2-low early breast cancer
Trial in progress
- Design: Poster / trial-in-progress